论文部分内容阅读
目的探讨孟鲁司特治疗难治性哮喘的临床疗效。方法选择2009年10月至2010年6月收治的难治性哮喘患者78例,随机将患者分为研究组和对照组。2组均有常规治疗(激素和β2受体激动剂),治疗组在基础上加用孟鲁司特片,每晚10mg口服,2周为一个疗程,观察比较两组疗效及相关指标。结果与对照组相比,研究组的显效率、总有效率和FEV1/FVC%值占估计值的百分比均明显提高,差异均有统计学意义(P<0.05)。结论孟鲁司特在治疗难治性哮喘的过程中表现出较好的临床疗效,且副作用小,是难治性哮喘患者的药物添加治疗首选。
Objective To investigate the clinical efficacy of montelukast in the treatment of refractory asthma. Methods 78 patients with refractory asthma admitted from October 2009 to June 2010 were randomly divided into study group and control group. Both groups had conventional treatment (hormones and β2 receptor agonists). The treatment group was given montelukast tablets on the basis of 10 mg per night orally for 2 weeks for one course of treatment. The curative effect and related indexes of the two groups were observed and compared. Results Compared with the control group, the markedly effective rate, total effective rate and FEV1 / FVC% of the study group were significantly higher than the control group, with statistical significance (P <0.05). Conclusion Montelukast shows better clinical efficacy in the treatment of refractory asthma with less side effects and is the first choice for drug addiction treatment in patients with refractory asthma.